Traumatic Brain Injury - Pipeline Review, Q2 2011

Document Sample
Traumatic Brain Injury - Pipeline Review, Q2 2011 Powered By Docstoc
					Traumatic Brain Injury – Pipeline Review, Q2 2011




        Traumatic Brain Injury - Pipeline Review, Q2 2011
                                                                                          Reference Code: GMDHC1080IDB

                                                                                          Publication Date: April 2011




Traumatic Brain Injury – Pipeline Review, Q2 2011                                               GMDHC1080IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                         Page(1)
Traumatic Brain Injury – Pipeline Review, Q2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                       2
List of Tables                                                                                                          7
List of Figures                                                                                                         8
Introduction                                                                                                            9
     Global Markets Direct Report Coverage                                                                              9
Traumatic Brain Injury Overview                                                                                        10
Therapeutics Development                                                                                               11
     An Overview of Pipeline Products for Traumatic Brain Injury                                                       11
Traumatic Brain Injury Therapeutics under Development by Companies                                                     13
Traumatic Brain Injury Therapeutics under Investigation by Universities/Institutes                                     15
Late Stage Products                                                                                                    18
     Comparative Analysis                                                                                              18
Mid Clinical Stage Products                                                                                            19
     Comparative Analysis                                                                                              19
Early Clinical Stage Products                                                                                          20
     Comparative Analysis                                                                                              20
Discovery and Pre-Clinical Stage Products                                                                              21
     Comparative Analysis                                                                                              21
Traumatic Brain Injury Therapeutics - Products under Development by Companies                                          22
Traumatic Brain Injury Therapeutics - Products under Investigation by Universities/Institutes                          24
Companies Involved in Traumatic Brain Injury Therapeutics Development                                                  26
     Abbott Laboratories                                                                                               26
     Sangart, Inc.                                                                                                     26
     Alseres Pharmaceuticals, Inc.                                                                                     27
     Acorda Therapeutics, Inc.                                                                                         27
     Oxygen Biotherapeutics, Inc.                                                                                      28
     Proneuron Biotechnologies, Inc.                                                                                   28
     Neuren Pharmaceuticals Limited                                                                                    29
     Transition Therapeutics Inc.                                                                                      29
     Allon Therapeutics Inc.                                                                                           30
     Stem Cell Therapeutics Corp.                                                                                      30
     axxonis Pharma AG                                                                                                 31
     M et P Pharma AG                                                                                                  31
     D-Pharm Ltd.                                                                                                      32
     KeyNeurotek Pharmaceuticals AG                                                                                    32
     Xytis Inc.                                                                                                        33
     vasopharm GmbH                                                                                                    33
     Innogene Kalbiotech Pte Ltd.                                                                                      34
     Maas Biolab                                                                                                       34
     M's Science Corporation                                                                                           35
     NeuroHealing Pharmaceuticals Inc.                                                                                 35
     Sinapis Pharma, Inc                                                                                               36
     BHR Pharma, LLC.                                                                                                  36
     Cognosci, Inc.                                                                                                    37
Traumatic Brain Injury - Therapeutics Assessment                                                                       38
     Assessment by Monotherapy Products                                                                                38
     Assessment by Route of Administration                                                                             39


Traumatic Brain Injury – Pipeline Review, Q2 2011                                               GMDHC1080IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(2)
Traumatic Brain Injury – Pipeline Review, Q2 2011


     Assessment by Molecule Type                                                                                 41
Drug Profiles                                                                                                    43
     Anatibant - Drug Profile                                                                                    43
          Product Description                                                                                    43
          Mechanism of Action                                                                                    43
          R&D Progress                                                                                           43
     Inosine - Drug Profile                                                                                      44
          Product Description                                                                                    44
          Mechanism of Action                                                                                    44
          R&D Progress                                                                                           44
     NBT-723 - Drug Profile                                                                                      45
          Product Description                                                                                    45
          Mechanism of Action                                                                                    45
          R&D Progress                                                                                           45
     ProgestoMat - Drug Profile                                                                                  46
          Product Description                                                                                    46
          Mechanism of Action                                                                                    46
          R&D Progress                                                                                           46
     DP-b99 - Drug Profile                                                                                       47
          Product Description                                                                                    47
          Mechanism of Action                                                                                    47
          R&D Progress                                                                                           47
     Oxycyte Emulsion - Drug Profile                                                                             48
          Product Description                                                                                    48
          Mechanism of Action                                                                                    48
          R&D Progress                                                                                           48
     Kalsolac - Drug Profile                                                                                     50
          Product Description                                                                                    50
          Mechanism of Action                                                                                    50
          R&D Progress                                                                                           50
     VAS203 - Drug Profile                                                                                       51
          Product Description                                                                                    51
          Mechanism of Action                                                                                    51
          R&D Progress                                                                                           51
     GGF2 - Drug Profile                                                                                         52
          Product Description                                                                                    52
          Mechanism of Action                                                                                    52
          R&D Progress                                                                                           52
     KN38-7271 - Drug Profile                                                                                    54
          Product Description                                                                                    54
          Mechanism of Action                                                                                    54
          R&D Progress                                                                                           54
     NH001 - Drug Profile                                                                                        55
          Product Description                                                                                    55
          Mechanism of Action                                                                                    55
          R&D Progress                                                                                           55
     MC116 - Drug Profile                                                                                        56
          Product Description                                                                                    56




Traumatic Brain Injury – Pipeline Review, Q2 2011                                         GMDHC1080IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                         Page(3)
Traumatic Brain Injury – Pipeline Review, Q2 2011


          Mechanism of Action                                                                                    56
          R&D Progress                                                                                           56
     MC113 - Drug Profile                                                                                        57
          Product Description                                                                                    57
          Mechanism of Action                                                                                    57
          R&D Progress                                                                                           57
     NNZ-2566 - Drug Profile                                                                                     58
          Product Description                                                                                    58
          Mechanism of Action                                                                                    58
          R&D Progress                                                                                           58
     Vaprisol - Drug Profile                                                                                     59
          Product Description                                                                                    59
          Mechanism of Action                                                                                    59
          R&D Progress                                                                                           59
     Rosuvastatin - Drug Profile                                                                                 60
          Product Description                                                                                    60
          Mechanism of Action                                                                                    60
          R&D Progress                                                                                           60
     Minocycline - Drug Profile                                                                                  61
          Product Description                                                                                    61
          Mechanism of Action                                                                                    61
          R&D Progress                                                                                           61
     Recombinant Human Growth Hormone - Drug Profile                                                             62
          Product Description                                                                                    62
          Mechanism of Action                                                                                    62
          R&D Progress                                                                                           62
     Atorvastatin - Drug Profile                                                                                 63
          Product Description                                                                                    63
          Mechanism of Action                                                                                    63
          R&D Progress                                                                                           63
     Premarin - Drug Profile                                                                                     65
          Product Description                                                                                    65
          Mechanism of Action                                                                                    65
          R&D Progress                                                                                           65
     NeuroSTAT - Drug Profile                                                                                    66
          Product Description                                                                                    66
          Mechanism of Action                                                                                    66
          R&D Progress                                                                                           66
     Methamphetamine - Drug Profile                                                                              67
          Product Description                                                                                    67
          Mechanism of Action                                                                                    67
          R&D Progress                                                                                           67
     Autologous Stem Cell - Drug Profile                                                                         68
          Product Description                                                                                    68
          Mechanism of Action                                                                                    68
          R&D Progress                                                                                           68
     Epoetin Alfa - Drug Profile                                                                                 69
          Product Description                                                                                    69




Traumatic Brain Injury – Pipeline Review, Q2 2011                                         GMDHC1080IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                         Page(4)
Traumatic Brain Injury – Pipeline Review, Q2 2011


          Mechanism of Action                                                                                    69
          R&D Progress                                                                                           69
     MP4OX - Drug Profile                                                                                        70
          Product Description                                                                                    70
          Mechanism of Action                                                                                    70
          R&D Progress                                                                                           70
     TT-301 - Drug Profile                                                                                       72
          Product Description                                                                                    72
          Mechanism of Action                                                                                    72
          R&D Progress                                                                                           72
     NimoGel - Drug Profile                                                                                      73
          Product Description                                                                                    73
          Mechanism of Action                                                                                    73
          R&D Progress                                                                                           73
     BHR-100 - Drug Profile                                                                                      75
          Product Description                                                                                    75
          Mechanism of Action                                                                                    75
          R&D Progress                                                                                           75
     AL-209 - Drug Profile                                                                                       76
          Product Description                                                                                    76
          Mechanism of Action                                                                                    76
          R&D Progress                                                                                           76
     IM Risperidone - Drug Profile                                                                               77
          Product Description                                                                                    77
          Mechanism of Action                                                                                    77
          R&D Progress                                                                                           77
     Darbepoetin Alfa - Drug Profile                                                                             78
          Product Description                                                                                    78
          Mechanism of Action                                                                                    78
          R&D Progress                                                                                           78
     Sodium Lactate - Drug Profile                                                                               79
          Product Description                                                                                    79
          Mechanism of Action                                                                                    79
          R&D Progress                                                                                           79
     Botulinum Toxin - Drug Profile                                                                              80
          Product Description                                                                                    80
          Mechanism of Action                                                                                    80
          R&D Progress                                                                                           80
     Progesterone - Drug Profile                                                                                 81
          Product Description                                                                                    81
          Mechanism of Action                                                                                    81
          R&D Progress                                                                                           81
     Mifepristone - Drug Profile                                                                                 82
          Product Description                                                                                    82
          Mechanism of Action                                                                                    82
          R&D Progress                                                                                           82
     Perfalgan - Drug Profile                                                                                    83
          Product Description                                                                                    83




Traumatic Brain Injury – Pipeline Review, Q2 2011                                         GMDHC1080IDB / Pub April 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                         Page(5)
Traumatic Brain Injury – Pipeline Review, Q2 2011


          Mechanism of Action                                                                                                       83
          R&D Progress                                                                                                              83
     Cop-1 Neuroprotective Vaccine - Drug Profile                                                                                    84
          Product Description                                                                                                       84
          Mechanism of Action                                                                                                       84
          R&D Progress                                                                                                              84
     EG-1964 - Drug Profile                                                                                                          85
          Product Description                                                                                                       85
          Mechanism of Action                                                                                                       85
          R&D Progress                                                                                                              85
     COG1410 - Drug Profile                                                                                                         86
          Product Description                                                                                                       86
          Mechanism of Action                                                                                        
				
DOCUMENT INFO
Description: Traumatic Brain Injury - Pipeline Review, Q2 2011 Summary Global Markets Direct’s, 'Traumatic Brain Injury - Pipeline Review, Q2 2011', provides an overview of the Traumatic Brain Injury therapeutic pipeline. This report provides information on the therapeutic development for Traumatic Brain Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury. 'Traumatic Brain Injury - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Traumatic Brain Injury. - A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Traumatic Brain Injury pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury. - Identify emerging
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries